Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8076355 | 0.89 | NPC1 (0.79) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL1114367 | 0.89 | NPC1 (0.79) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL28318457 | 0.88 | NPC1 (0.55) | NPC1KMT2ASMN1; SMN2ALOX5MAPT | |
| SCHEMBL15053660 | 0.85 | NPC1 (0.59) | NPC1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL13144461 | 0.84 | NPC1 (0.73) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL5095881 | 0.83 | NPC1 (0.71) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL584234 | 0.83 | NPC1 (0.71) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL7683393 | 0.83 | NPC1 (0.71) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL1099317 | 0.83 | HTT (0.53) | NPC1KMT2ASMN1; SMN2ALOX5MAPT | |
| SCHEMBL584503 | 0.82 | NPC1 (0.69) | NPC1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010034740-A1 | (R)-3-(N,N-DIMETHYLAMINO)PYRROLIDINE DERIVATIVES | PALAU PHARMA, S.A. (ES) | 2010-04-01 | — | — | WO | disclosed |
| EP-2132184-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104754-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | NPC1 474/4885CA12 1895/4885CA1 2841/4885 |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | NPC1 3263/4885CA12 4601/4885CA1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.